RISK-BENEFIT ANALYSIS AND RISK MINIMIZATION OF QUINAPRIL: A REVIEW
Anjo Sunny1, M. Arif Khan1, Darpelly Mahesh1, Nikhil Singh Chauhan1, Ritu Mishra1, Namindla Presila1 & Asa Samuel1 Show affiliations
- National Institute of Pharmaceutical Education and Research, India
American Journal of Pharmacology and Toxicology, Volume 9, Issue 1, pp. 68–74 · doi.org/10.3844/ajptsp.2014.68.74
Abstract
The purpose of this review is to give the readers an insight about the risks and benefits of ’quinapril’, a potent Angiotensin Converting Enzyme Inhibitor (ACEI). Quinapril is a highly effective novel drug indicated for treatment of congestive heart failure and hypertension. Despite of the fact that safety profile is quite well with low incidence of adverse effects, an attempt has been made to minimize the risks and subsequently minimizing the adverse consequences of this competitive inhibitor, thereby increasing the benefits of this enzyme inhibitor in day to day clinical practice.
Licence and reuse
Open access. This article is licensed under a Creative Commons Attribution 3.0 Licence (CC BY 3.0), as printed on the article, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original authors and the source. No permission is needed.
How to reuse this articleResponses (0)
About this article
Sunny, A., Khan, M. A., Mahesh, D., Chauhan, N. S., Mishra, R., Presila, N. & Samuel, A. (2014). RISK-BENEFIT ANALYSIS AND RISK MINIMIZATION OF QUINAPRIL: A REVIEW. American Journal of Pharmacology and Toxicology, 9(1), 68–74. https://doi.org/10.3844/ajptsp.2014.68.74
- Licence
- CC BY 3.0
- Issue
- Volume 9, Issue 1
- Policies
- Editorial independenceUse of generative AIData availabilityAppeals and complaints
- Version
- Version of record